Primary Assessment Method
Number of patients screened	24
Number of patients enrolled	18
Number of patients evaluable for toxicity	18
Number of patients evaluated for efficacy	5 for radiographic assessment, 15 for PFS/OS
Evaluation method	RECIST 1.1; Tumor Marker
Response assessment, CR	0 (0%)
Response assessment, PR	1 (20%)
Response assessment, SD	2 (40%)
Response assessment, PD	2 (40%)
Median duration assessment, PFS	5.46 months (CI: 1.61-8.32)
Median duration assessment, OS	12.2 months (CI: 3.48-13.51)